What is the evidence base for BPC-157 Capsule (Delayed Release)?

BPC-157 Capsule (Delayed Release)'s evidence base sits at preclinical + limited human. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The sourcing / quality / procurement interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

Is BPC-157 Capsule (Delayed Release) safe during pregnancy or breastfeeding?

BPC-157 Capsule (Delayed Release), like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

What route should I use for BPC-157 Capsule (Delayed Release)?

BPC-157 Capsule (Delayed Release) is delivered by oral. The oral route engages enteric receptors and the gut-brain axis directly. The choice depends on target system and convenience.

What are the procurement red flags for BPC-157 Capsule (Delayed Release)?

Six markers to evaluate when sourcing BPC-157 Capsule (Delayed Release): lot-specific COAs available; HPLC purity ≥98% confirmed; mass spec confirming 1419.5 Da; endotoxin testing for SubQ-route material; physical address and regulatory disclosure on vendor site; cold-chain shipping options. Multiple missing markers = walk away. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

How does BPC-157 Capsule (Delayed Release) compare to BPC-157 and TB-500?

BPC-157 Capsule (Delayed Release) (Stable gastric pentadecapeptide (oral), ~4 hr half-life, 500 mcg-1 mg typical dose) differs from peers in the comparison table above. The principal points of difference relative to BPC-157 and TB-500 are mechanism, half-life, and target system. The full comparison is in the table above; specific stack selection depends on which dimension matters for the application.

Home/ Compounds/ BPC-157 Capsule (Delayed Release)

BPC-157 Capsule (Delayed Release)

Sourcing Guide

Sourcing BPC-157 Capsule (Delayed Release) from research-grade vendors requires the QC framework that governs any peptide procurement: certificate of analysis review, lot-specific verification, third-party laboratory issuance, and — critically — endotoxin testing for injectable material. An oral delayed-release format of BPC-157 optimized for gut-targeted action and gut-brain axis effects. The three-tier vendor market (pharmaceutical-grade compounded, reputable research-grade, grey-market) is described below.

Sourcing / Quality / Procurement Applications

HPLC PurityCOA ReviewPricing AnalysisStorage ProtocolMass Spectrometry Verification

Key Takeaways

Procurement lens: BPC-157 Capsule (Delayed Release) sourcing requires lot-specific COA, HPLC purity ≥98%, mass spec confirmation matching 1419.5 Da.
Mechanism: Same pentadecapeptide as injectable BPC-157, formulated for delayed release in the small intestine.
Storage: lyophilised at -20°C for 18-24 months; reconstituted at 4°C for 14-28 days.
Vendor tier: pharmaceutical-grade compounded > reputable research-grade > grey-market (3-5x cost differential; quality differential substantially larger).
Sourcing-validated stack partners: BPC-157, TB-500, GHK-Cu.

Sourcing / Quality / Procurement Mechanism

Same pentadecapeptide as injectable BPC-157, formulated for delayed release in the small intestine. Engages enteric receptors directly, supporting gut barrier integrity and signalling along the vagal gut-brain axis. Quality control discipline for BPC-157 Capsule (Delayed Release) starts with mechanism understanding: which assays detect counterfeits, which impurities matter for the intended use, and which storage conditions preserve activity. The subsections work through HPLC purity, COA evaluation, reconstitution protocol, and vendor selection.

Reconstitution and storage protocols

BPC-157 Capsule (Delayed Release) is typically supplied lyophilised in glass vials for reconstitution with bacteriostatic water. Standard reconstitution: dissolve at 1–2 mg/mL, store reconstituted material at 4°C, and use within 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Lyophilised storage at −20°C extends shelf life to 18–24 months for most peptides in this class.

COA evaluation and red flags

Acceptable BPC-157 Capsule (Delayed Release) certificates of analysis specify: (1) lot number matching the vial, (2) HPLC purity with chromatographic trace, (3) mass spec confirmation, (4) endotoxin testing for SubQ-route use, and (5) issuance from an accredited third-party laboratory. Template COAs that cannot be traced to a specific lot, COAs missing endotoxin data for injectable material, and COAs issued by the vendor's own laboratory rather than a third party are all sourcing red flags.

HPLC purity and analytical identity

Minimum acceptable HPLC purity for BPC-157 Capsule (Delayed Release) is ≥98% in research-grade material. Mass spec confirmation should show the characteristic m/z of 1419.5 (M+H)+. Contaminant peaks above 1% in the HPLC trace warrant quantification on the COA and — ideally — structural identification of the major impurities.

Sourcing / Quality / Procurement Applications

Mass Spectrometry Verification

For users targeting mass spectrometry verification, the sourcing question is whether the chosen vendor consistently delivers analytical-spec material across lots. Repeated re-orders from the same vendor with mid-cycle COA spot-checks is the procurement pattern that catches lot drift before it affects results.

Red Flag Detection

Pharmaceutical-grade compounded BPC-157 Capsule (Delayed Release) is the lowest-risk sourcing path for red flag detection use where the route permits, particularly for users with clinical supervision. Research-grade material from accredited vendors is the practical alternative; grey-market sourcing is not appropriate for this application.

HPLC Purity

Sourcing BPC-157 Capsule (Delayed Release) for hplc purity use requires the same QC discipline as any peptide procurement: lot-specific COA, HPLC purity ≥98%, mass spec confirmation, endotoxin testing for injectable routes. Application-specific use does not relax the sourcing standard.

Pricing Analysis

For users targeting pricing analysis, the sourcing question is whether the chosen vendor consistently delivers analytical-spec material across lots. Repeated re-orders from the same vendor with mid-cycle COA spot-checks is the procurement pattern that catches lot drift before it affects results.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	Oral	500 mcg-1 mg	8–12 weeks on / 4 weeks off
Conservative starter	Oral	300 mcg-1 mg	4–6 weeks initial cycle
Sourcing Guide focus	Oral	500 mcg-1 mg	1x daily AM, fasted
Maintenance phase	Oral	350 mcg-1 mg	Ongoing with periodic pauses

Dose timing for BPC-157 Capsule (Delayed Release) is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

BPC-157 Capsule (Delayed Release) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from experienced peptide buyers.

BPC-157 Capsule (Delayed Release) + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with BPC-157 Capsule (Delayed Release)'s mechanism in sourcing / quality / procurement protocols.
BPC-157 Capsule (Delayed Release) + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with BPC-157 Capsule (Delayed Release)'s mechanism in sourcing / quality / procurement protocols.
BPC-157 Capsule (Delayed Release) + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with BPC-157 Capsule (Delayed Release)'s mechanism in sourcing / quality / procurement protocols.
BPC-157 Capsule (Delayed Release) + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with BPC-157 Capsule (Delayed Release)'s mechanism in sourcing / quality / procurement protocols.

Safety & Regulatory Status

WADA: Banned (2022→) FDA: Unapproved (Research Only) Research: Preclinical + Limited Human

Same profile as injectable BPC-157. Best taken away from food for absorption.

Lens-specific safety considerations for sourcing / quality / procurement use of BPC-157 Capsule (Delayed Release): Same profile as injectable BPC-157. Best taken away from food for absorption. Additional sourcing / quality / procurement monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Sikirić et al. — BPC 157 cytoprotection and tissue repair

PMID 10404425

Supporting

BPC 157: clinical applications and mechanism

PMID 34209680

BPC-157 Capsule (Delayed Release) vs Related Peptides

Compound	Profile	Onset	Best For
BPC-157 Capsule (Delayed Release)	Stable gastric pentadecapeptide (oral)	~4 hr	Sourcing Guide
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite

Frequently Asked Questions

Reconstitution best practices?

Use sterile bacteriostatic water (0.9% benzyl alcohol). Inject the BAC water down the side of the vial, not directly onto the lyophilised powder. Allow gentle dissolution; do not shake vigorously — swirl the vial. Label the reconstituted vial with concentration and date.

Lot variability across orders?

Even reputable vendors show some lot-to-lot variability. The QC-disciplined practice is to spot-check a fresh COA against the prior lot when re-ordering, and to track perceived response across lots. Substantial drift in subjective effects on a stable dose with a stable protocol often traces back to material quality rather than physiology.

Pharmaceutical-grade versus research-grade?

Pharmaceutical-grade is GMP-manufactured, COA-backed, prescription-dispensed material with comprehensive quality assurance. Research-grade is laboratory-purpose, COA-backed, not dispensed under prescription. Quality varies substantially between research-grade vendors; pharmaceutical-grade has a tighter quality distribution and a higher price.

What should I check on a BPC-157 Capsule (Delayed Release) COA?

Acceptable certificates: lot-specific (not template), HPLC purity ≥98%, mass spec confirmation matching 1419.5 Da, endotoxin testing for injectable routes, accredited third-party lab issuance. Template COAs and missing endotoxin data are red flags.

What are the safety considerations for BPC-157 Capsule (Delayed Release)?

Same profile as injectable BPC-157. Best taken away from food for absorption. For sourcing and quality-control use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. BPC-157 Capsule (Delayed Release)'s ~4 hr pharmacokinetic profile and oral administration route influence the side-effect profile in predictable ways.

How does BPC-157 Capsule (Delayed Release)'s half-life affect dosing?

BPC-157 Capsule (Delayed Release) has a plasma half-life of ~4 hr, which is moderate, supporting once-daily dosing in most protocols. The receptor occupancy curve under 1x daily am, fasted dosing at 500 mcg-1 mg per dose explains the typical onset timeline for sourcing and quality-control endpoints.

Clinical Protocol

Start a BPC-157 Capsule (Delayed Release) Protocol

Alukard provides GMP-certified physician-supervised sourcing with GMP-certified BPC-157 Capsule (Delayed Release) and Pharmaceutical-grade compounds with full COA documentation.

Get Protocol

Quick Facts

Molecular weight: 1419.5 Da
Sequence length: 15 aa
Half-life: ~4 hr
WADA: Banned (2022→)
FDA: Unapproved (Research Only)
Research: Preclinical + Limited Human

Stack Partners

BPC-157

TB-500

GHK-Cu

Ipamorelin

Semax

Research Note

All sourcing / quality / procurement applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for BPC-157 Capsule (Delayed Release) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

GMP-certified physician-supervised sourcing

Start Your Sourcing / Quality / Procurement Protocol for BPC-157 Capsule (Delayed Release)

Alukard provides GMP-certified physician-supervised sourcing with Pharmaceutical-grade compounds with full COA documentation.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised